替吉奥治疗二线晚期鼻咽癌临床疗效观察(2)
 |
| 第1页 |
参见附件。
[3]Au E，Ang PT.A phase II trial of 5-Fu and cisplatin in recurrent or metastatic nasopharyngeal carcinoma[J].Ann Oncol，1994，5：87-89.
[4]Kwong D，Sham J，Choy D.The effect of loco-regional control on distant metastatic dissemination in carcinoma of the nasopharynx：an analysis of 1301 patients[J].Int J Radiat Oncol Biol Phys，1994，30(5)：1029-1036.
[5]Peters GJ，Noordhuis P，Van Kuilenburg AB，et a1.Pharmacokinetics of S-1，all oral formulation of ftorafur，oxonic acid and 5-ehlom2，4-dihydroxypyridine(molar ratio l：0.4：1)in patients with solid tumors[J].Cancer Chemother Pharmaeol，2003，52(1)：1-12.
[6]Pan Q，Gorin MA，Teknos TN.Pharmacotherapy of head and neck squamous cell carcinoma[J].Expert Opin Pharmacother，2009，10 (14)：2291-2302.
[7]Ohashi T，Ohnishi M，Tanahashi S，et a1.Efficacy and toxicity of concurrent chemoradiotherapy with nedaplatin and S-l for head and neck cancer[J].Jpn J Clin Oncol，201l，4l(3)：348-352.
[8]Shirasaki T，Maruya S，Namba A，et a1.Treatment results of chemotherapy with S-1 for head and neck cancer[J].Gan To Kagaku Ryoho，2009，36(2)：237-240.
编辑/申磊
您现在查看是摘要介绍页，详见PDF附件。